Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cetraxal, to treat Acute Otitis Externa without risk from steroids or preservatives
Subscribe to our email newsletter
Salvat and WraSer Pharmaceuticals have entered into an exclusive license agreement to market Salvat’s Cetraxal in the US, for a period of ten years.
The company said that Cetraxal is the only ciprofloxacin-alone solution approved by the FDA for treating AOE, providing high efficacy without risk from steroids or preservatives. Cetraxal is available in a single-dispensing container that ensures safe and accurate dosing.
Heath Wray, President of WraSer Pharmaceuticals, said: “WraSer is extremely excited to bring this new product to the US market. We are confident that patients will appreciate the ease of use with the single-dose dispenser, and physicians will be confident in a safe, effective treatment for swimmer’s ear utilizing a steroid-free, proven antibiotic therapy.”
Earlier in May 2009, Cetraxal had received FDA approval as a new treatment for Acute Otitis Externa (AOE) or swimmer’s ear.